Abstract：At present, the incidence and mortality rate of hepatocellular carcinoma (HCC) are on the rise. HCC is characterized by insidious onset, difficult early diagnosis, and rapid progression. Surgical treatment can only be used for less than 30% of patients, therefore non-surgical treatment used for prolonging the survival time of patients with advanced HCC is significant. As one of the non-surgical treatment of advanced HCC, Sorafenib, can only prolong overall survival time for several months. More than two thirds of patients with advanced HCC have died from liver failure due to the progression of intrahepatic tumors; local treatment can control the progress of intrahepatic tumors, but relapse is common. At present, a large number of clinical trials about combination Sorafenib with locoregional therapy have been carried out at home and abroad. This review, by describing the theory of combination therapy and the results of clinical trials, intends to reach a feasible conclusion that can be used as a reference for clinical doctors to make the treatment plan.
[1] Burrel M，Reig M，Forner A，et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation（TACE）using Drug Eluting Beads. Implications for clinical practice and trial design [J]. J Hepatol，2012， 56（6）：1330.
[2] Bosetti C，Turati F，La Vecchia C. Hepatocellular carcinoma epidemiology [J]. Best Pract Res Clin Gastroenterol，2014， 28（5）：753-770.
[3] Zhu RX，Seto WK，Lai CL，et al. Epidemiology of hepatocellular carcinoma in the asia-pacific region [J]. Gut Liver，2016，10（3）：332-339.
[4] Cha C. Surgical therapy for hepatocellular carcinoma：formulating a rational approach. [J]. J Clin Gastroenterol，2013，47 Suppl（125）：S30-S36.
[5] Llovet JM，Ricci S，Mazzaferro V，et al. Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med，2008， 359（4）：378-390.
[6] Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phase Ⅲ randomised，double-blind，placebo-controlled trial. [J]. Lancet Oncology，2009，10（1）：25-34.
[7] Zhang S，Yue M，Shu R，et al. Recent advances in the management of hepatocellular carcinoma [J]. J BUON，2016， 21（2）：307-311.
[8] Liu L，Cao Y，Chen C，et al. Sorafenib Blocks the RAF/MEK/ERK pathway，inhibits tumor angiogenesis，and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J]. Cancer Res，2007，66（24）：11851-11858.
[9] Lee S，Kim BK，Kim SU，et al. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. [J]. Plos One，2013，8（10）： e77240.
[10] European Association for the Study of the Liver，European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines：management of hepatocellular carcinoma [J]. J Hepatol，2012，56（4）：908-943.
[11] Liu K，Min XL，Peng J，et al. The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma [J]. J Clin Med Res，2016，8（4）：297-302.
[12] Chao Y，Chung YH，Han G，et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma：final results of the START trial [J]. Int J Cancer，2015，136（6）：1458-1467.
[13] Lencioni R，Llovet JM，Han G，et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC：the SPACE trial [J]. J Hepatol，2016，64（5）：1090-1098.
[14] Erhardt A，Kolligs F，Dollinger M，et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma：results of the multicenter，phase Ⅱ SOCRATES trial [J]. Cancer Chemother Pharmacol，2014，74（5）：947-954.
[15] Bruix J，Sherman M. Management of hepatocellular carcinoma：an update. american association for the study of liver diseases（AASLD） practice guideline [J]. Hepatology，2011，53：1020-1035.
[16] Lin ZZ，Shau WY，Hsu C，et al. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size [J]. PloS One，2013，8（11）： e80276.
[17] Decadt B，Siriwardena AK. Radiofrequency ablation of liver tumours：systematic review [J]. Lancet Oncology，2004， 5（9）：550-560.
[18] Chen L，Sun J，Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma：current status [J]. Cancer Lett，2016，370（1）：78-84.
[19] Wang Y，Deng T，Zeng L，et al. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma：a meta-analysis [J]. Hepatol Res，2016，46（1）：58-71.
[20] Bruix J，Takayama T，Mazzaferro V，et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation （STORM）：a phase 3，randomised，double-blind，placebo-controlled trial [J]. Lancet Oncol，2015，16（13）：1344-1354.
[21] Kan X，Jing Y，Wan QY，et al. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma [J]. Eur Rev Med Pharmacol Sci，2015，19（2）：247-255.
[22] Giorgio A，Merola MG，Montesarchio L，et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein：a western randomized controlled trial [J]. Anticancer Res，2016，36（11）：6179-6183.
[23] Benson R，Madan R，Kilambi R，et al. Radiation induced liver disease：a clinical update [J]. J Egypt Natl Canc Inst，2016，28（1）：7-11.
[24] Tang WY，Chau SP，Tsang WP，et al. The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells [J]. Oncol Rep，2004，12（6）：1349-1354.
[25] Gorski DH，Beckett MA，Jaskowiak NT，et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation [J]. Cancer Res，1999，59（59）：3374-3378.
[26] Yu W，Gu K，Yu Z，et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. [J]. Cancer Letters，2013，329（1）：109-117.
[27] Dai XF，Ding J，Zhang RG，et al. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway [J]. Int J Radiat Biol，2013，89（9）：724-731.
[28] Chen SW，Lin LC，Kuo YC，et al. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma [J]. Int J Radiat Oncol Biol Phys，2014，88（5）：1041-1047.
[29] Brade AM，Ng S，Brierley J，et al. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma [J]. Int J Radiat Oncol Biol Phys，2016，94（3）：580-587.
[30] Sangro B，Carpanese L，Cianni R，et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages：a European evaluation [J]. Hepatology，2011，54（3）：868-878.
[31] Kim EH，Kim BK，Kim DY，et al. Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma. [J]. Eur J Gastroenterol Hepatol，2013，25（4）：514.
[32] Chow PK，Poon D，Win KM. Multicenter phase Ⅱ study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma：the Asia-Pacific hepatocellular carcinoma trials group protocol 05（AHCC05）[J]. J Clin Oncol，2010，28（15）：1676-1680.
[33] Lorenzin D，Pravisani R，Leo CA，et al. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization [J]. Cancer Biother Radiopharm，2016，31（2）：65-69.
[34] Ricke J，Bulla K，Kolligs F，et al. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma：analysis of the European multicentre trial SORAMIC [J]. Liver Int，2015，35（2）：620-626.
2017, Vol. 14 
京公网安备 11010502046598号